HZNP Stock Recent News
HZNP LATEST HEADLINES
We're now into September, and that means many investors wonder if the September effect will be in place. This speaks to the historical trend of stocks underperforming in September compared to other months.
Some analysts and M&A experts say the settlement agreement doesn't mean that the FTC will stop baring its teeth at other large buyouts in the industry.
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement.
The Federal Trade Commission will allow Amgen to continue a $27.8 billion purchase of Horizon Therapeutics. The companies anticipate closing the deal in the fourth quarter.
Shares of Horizon Therapeutics PLC (NASDAQ: HZNP) are trading materially up today after the FTC allowed Amgen Inc (NASDAQ: AMGN) to move forward with its $27.8 billion acquisition of the biopharmaceutical company.
The agency previously argued the merger could harm patients who are prescribed Horizon's two fastest-growing drugs.
The Federal Trade Commission makes provision that prohibits “bundling” discounts for some medications.
CNBC's Emily Wilkins joins 'Squawk Box' with the latest news.
The Federal Trade Commission reached a deal with Amgen Inc. AMGN, -0.60% to approve its $27.8 billion acquisition of Horizon Therapeutics plc, HZNP, -0.07% the agency announced Friday.
The U.S. Federal Trade Commission has allowed drugmaker Amgen Inc to move ahead with its $27.8 billion deal to buy Horizon Therapeutics , CNBC reported on Friday.